Literature DB >> 15300915

Effects of dendritic cells transfected with full-length wild-type p53 and stimulated by gastric cancer lysates on immune response.

Hua-Wen Sun1, Qi-Bing Tang, Yong-Jun Cheng, Sheng-Qian Zou.   

Abstract

AIM: To investigate the effects of dendritic cells (DCs) transfected with full-length wild-type p53 and stimulated by gastric cancer lysates on immune response.
METHODS: The wild-type p53 was transduced to DCs with adenovirus, and the DCs were stimulated by gastric cancer lysates. The surface molecules (B7-1, B7-2, MHC-I, MHC-II) of all DCs were detected by FACS, and the ability of the DCs to induce efficient and specific immunological response in anti-51Cr-labeled target cells was studied. BALB/c mice injected with DCs and Mk28 were established, and CTL response in mice immunized with Lywt-p53DC was evaluated. Tumor-bearing mice were treated with Lywt-p53DC.
RESULTS: The surface molecules of Lywt-p53DC had a high expression of B7-1 (86.70 +/- 0.07%), B7-2 (18.77 +/- 0.08%), MHC-I (87.20 +/- 0.05%) and MHC-II (56.70 +/- 0.07%); T lymphocytes had a specific CTL lysis ability induced by Lywt-p53DC; the CTL lysis rate was as high as 81%. The immune protection of Lywtp-53DC was obvious, the tumor diameter in Lywtp-53DC group was 3.10 +/- 0.31 mm, 2.73 +/- 0.23 mm, 3.70 +/- 0.07 mm on d 13, 16 and 19, respectively, which were smaller than control, DC, wtp53DC and LyDC group (P<0.05). Tumor growth rate in Lywtp53DC group was slower than that in other groups (P<0.05).
CONCLUSION: DCs transfected with wild-type p53 and stimulated by gastric cancer lysates have specific CTL killing activity. Copyright 2004 The WJG Press ISSN

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15300915      PMCID: PMC4572172          DOI: 10.3748/wjg.v10.i17.2595

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  16 in total

1.  Peptides derived from the two regulatory domains of p53 are recognized by two p53-activating antibodies.

Authors:  Jean-Michel Portefaix; Maguy Del Rio; Claude Granier; Françoise Roquet; Bernard Pau; Isabelle Navarro-Teulon
Journal:  Peptides       Date:  2003-03       Impact factor: 3.750

2.  The ability of variant peptides to reverse the nonresponsiveness of T lymphocytes to the wild-type sequence p53(264-272) epitope.

Authors:  Thomas K Hoffmann; Douglas J Loftus; Koji Nakano; Markus J Maeurer; Kazuaki Chikamatsu; Ettore Appella; Theresa L Whiteside; Albert B DeLeo
Journal:  J Immunol       Date:  2002-02-01       Impact factor: 5.422

3.  Development of p53 protein transduction therapy using membrane-permeable peptides and the application to oral cancer cells.

Authors:  Toshihiko Takenobu; Kazuhito Tomizawa; Masayuki Matsushita; Sheng-Tian Li; Akiyoshi Moriwaki; Yun-Fei Lu; Hideki Matsui
Journal:  Mol Cancer Ther       Date:  2002-10       Impact factor: 6.261

4.  Identification of p53 peptides recognized by CD8(+) T lymphocytes from patients with bladder cancer.

Authors:  E Ferriès; F Connan; F Pagès; J Gaston; A M Hagnéré; A Vieillefond; N Thiounn; J Guillet; J Choppin
Journal:  Hum Immunol       Date:  2001-08       Impact factor: 2.850

5.  Dendritic cells transduced with full-length wild-type p53 generate antitumor cytotoxic T lymphocytes from peripheral blood of cancer patients.

Authors:  E Y Nikitina; J I Clark; J Van Beynen; S Chada; A K Virmani; D P Carbone; D I Gabrilovich
Journal:  Clin Cancer Res       Date:  2001-01       Impact factor: 12.531

6.  Detection of anti-p53 antibodies by ELISA using p53 synthetic or phage-displayed peptides.

Authors:  Jean Michel Portefaix; Cristina Fanutti; Claude Granier; Evelyne Crapez; Richard Perham; Jean Grenier; Bernard Pau; Maguy Del Rio
Journal:  J Immunol Methods       Date:  2002-01-01       Impact factor: 2.303

7.  Identification and design of p53-derived HLA-A2-binding peptides with increased CTL immunogenicity.

Authors:  T R Petersen; S Buus; S Brunak; M H Nissen; L A Sherman; M H Claesson
Journal:  Scand J Immunol       Date:  2001-04       Impact factor: 3.487

8.  Enhancement of tumor lysate- and peptide-pulsed dendritic cell-based vaccines by the addition of foreign helper protein.

Authors:  K Shimizu; E K Thomas; M Giedlin; J J Mulé
Journal:  Cancer Res       Date:  2001-03-15       Impact factor: 12.701

9.  Results of a phase I clinical study using autologous tumour lysate-pulsed monocyte-derived mature dendritic cell vaccinations for stage IV malignant melanoma patients combined with low dose interleukin-2.

Authors:  Hitomi Nagayama; Katsuaki Sato; Mariko Morishita; Kaoru Uchimaru; Naoki Oyaizu; Takeshi Inazawa; Tomoko Yamasaki; Makoto Enomoto; Takashi Nakaoka; Tetsuya Nakamura; Taira Maekawa; Akifumi Yamamoto; Shinji Shimada; Toshiaki Saida; Yutaka Kawakami; Shigetaka Asano; Kenzaburo Tani; Tsuneo A Takahashi; Naohide Yamashita
Journal:  Melanoma Res       Date:  2003-10       Impact factor: 3.599

10.  [Influence of dendritic cell infiltration on prognosis and biologic characteristics of progressing gastric cancer].

Authors:  Hai-li Huang; Ben-yan Wu; Wei-di You; Ming-shi Shen; Wen-ju Wang
Journal:  Zhonghua Zhong Liu Za Zhi       Date:  2003-09
View more
  1 in total

1.  Function of fibroblast growth factor 2 in gastric cancer occurrence and prognosis.

Authors:  Yang Li; Xiao-Bo Guo; Jin Shen Wang; Hong-Chang Wang; Le-Ping Li
Journal:  Mol Med Rep       Date:  2019-11-26       Impact factor: 2.952

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.